Global Anticoagulants Market (2018-2022 Edition)
Scope of the Report
The report entitled “Global Anticoagulants Market (2018-2022 Edition)” provides an in-depth analysis of the global anticoagulants market with description of market size and growth. The analysis include market share by treatment, by segment, and by products.
The report also provides an analysis of injectable and oral anticoagulants available in the market. Details of Lovenox, Arixtra, Xarelto, Eliquis, Pradaxa and Savaysa has been provided in the report in terms of their global sales.
A brief analysis of the US anticoagulants market has also been provided in terms of value and sales of top four oral anticoagulant drugs in the region.
Furthermore, the report also assesses the key opportunities available in the market and outline the market dynamics that are and will be accountable for growth of the industry. Growth of the global anticoagulants market has also been forecasted for the period 2018-2022, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
Bayer, BMS/Pfizer, Boehringher Ingelheim and Daiichi Sankyo are some of the key players operating in the global anticoagulants market, whose company profiling has been done in the report. This segment summarizes business overview, financial overview and the business strategies of the companies.
Company Coverage
The US
Executive Summary
Anticoagulants which are also known as blood thinners are drugs that are prescribed to prevent blood from clotting or stop existing clots from getting larger. The drugs prevent harmful clots forming in heart, veins or arteries. Formation of clots in the blood can lead to heart attack or stroke. These drugs are used to treat strokes, myocardial infarctions, pulmonary embolisms, disseminated intravascular coagulation (DIC) and deep vein thrombosis (DVT)- all potentially life-threatening conditions. Anticoagulants work by interrupting the process involved in the formation of blood clots.
The most commonly prescribed anticoagulant is Warfarin. Newer types of anticoagulants are also available and are becoming increasingly common. These include rivaroxaban (Xarelto), dabigatran (Pradaxa), apixaban (Eliquis), and edoxaban (Savaysa/Lixiana). Warfarin and the newer alternatives are taken as tablets or capsules. There's also an anticoagulant called heparin that can be given by injection.
The global anticoagulants market has increased over the years and is expected to grow in the next four years i.e. 2018-2022, particularly due to development of novel oral anticoagulants (NOACs). The global anticoagulants market is supported by various growth drivers such as growing aging population, rising prevalence of coagulant disorders, increasing demand for NOACs, rising awareness about anticoagulants, etc. Yet, the market faces some challenges which are obstructing the growth of the market. Some of the challenges are stringent regulations from regulatory bodies, high cost of oral anticoagulants, major side-effects associated with the drugs, etc.
The report entitled “Global Anticoagulants Market (2018-2022 Edition)” provides an in-depth analysis of the global anticoagulants market with description of market size and growth. The analysis include market share by treatment, by segment, and by products.
The report also provides an analysis of injectable and oral anticoagulants available in the market. Details of Lovenox, Arixtra, Xarelto, Eliquis, Pradaxa and Savaysa has been provided in the report in terms of their global sales.
A brief analysis of the US anticoagulants market has also been provided in terms of value and sales of top four oral anticoagulant drugs in the region.
Furthermore, the report also assesses the key opportunities available in the market and outline the market dynamics that are and will be accountable for growth of the industry. Growth of the global anticoagulants market has also been forecasted for the period 2018-2022, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
Bayer, BMS/Pfizer, Boehringher Ingelheim and Daiichi Sankyo are some of the key players operating in the global anticoagulants market, whose company profiling has been done in the report. This segment summarizes business overview, financial overview and the business strategies of the companies.
Company Coverage
- Bayer
- BMS/Pfizer
- Boehringher Ingelheim
- Daiichi Sankyo
The US
Executive Summary
Anticoagulants which are also known as blood thinners are drugs that are prescribed to prevent blood from clotting or stop existing clots from getting larger. The drugs prevent harmful clots forming in heart, veins or arteries. Formation of clots in the blood can lead to heart attack or stroke. These drugs are used to treat strokes, myocardial infarctions, pulmonary embolisms, disseminated intravascular coagulation (DIC) and deep vein thrombosis (DVT)- all potentially life-threatening conditions. Anticoagulants work by interrupting the process involved in the formation of blood clots.
The most commonly prescribed anticoagulant is Warfarin. Newer types of anticoagulants are also available and are becoming increasingly common. These include rivaroxaban (Xarelto), dabigatran (Pradaxa), apixaban (Eliquis), and edoxaban (Savaysa/Lixiana). Warfarin and the newer alternatives are taken as tablets or capsules. There's also an anticoagulant called heparin that can be given by injection.
The global anticoagulants market has increased over the years and is expected to grow in the next four years i.e. 2018-2022, particularly due to development of novel oral anticoagulants (NOACs). The global anticoagulants market is supported by various growth drivers such as growing aging population, rising prevalence of coagulant disorders, increasing demand for NOACs, rising awareness about anticoagulants, etc. Yet, the market faces some challenges which are obstructing the growth of the market. Some of the challenges are stringent regulations from regulatory bodies, high cost of oral anticoagulants, major side-effects associated with the drugs, etc.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Overview of Anticoagulants
2.1.1 Types of Anticoagulants
2.1.2 Novel Oral Anticoagulants
3. GLOBAL MARKET ANALYSIS
3.1 Global Anticoagulants Market Analysis
3.1.1 Global Anticoagulants Market by Value
3.1.2 Global Anticoagulants Market Share by Treatment
3.1.3 Global Anticoagulants Market Share by Segment (Oral Anticoagulants and others)
3.1.4 Global Anticoagulants Market Share by Products (Lovenox, Arixtra, Xarelto, Eliquis, Pradaxa, and Savaysa)
4. GLOBAL ANTICOAGULANTS PRODUCT ANALYSIS
4.1 Injectable Anticoagulants Product Analysis
4.1.1 Global Lovenox Market by Value
4.1.2 Global Arixtra Market by Value
4.2 Oral Anticoagulants Product Analysis
4.2.1 Global Xarelto Market by Value
4.2.2 Global Eliquis Market by Value
4.2.3 Global Pradaxa Market by Value
4.2.4 Global Savaysa Market by Value
5. REGIONAL ANALYSIS
5.1 The US Anticoagulants Market Analysis
5.1.1 The US Anticoagulants Market by Value
5.1.2 The US Anticoagulants Market by Products (Xarelto, Eliquis, Pradaxa, and Savaysa)
5.1.3 The US Xarelto Market by Value
5.1.4 The US Eliquis Market by Value
5.1.5 The US Pradaxa Market by Value
5.1.6 The US Savaysa Market by Value
6. COMPETITIVE LANDSCAPE
6.1 Global Top Oral Anticoagulants by Sales
6.2 Global Anticoagulants Market Players by Product Comparison
7. COMPANY PROFILE
7.1 Bayer Group
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 BMS/Pfizer
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Boehringher Ingelheim
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Daiichi Sankyo
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
2. INTRODUCTION
2.1 Overview of Anticoagulants
2.1.1 Types of Anticoagulants
2.1.2 Novel Oral Anticoagulants
3. GLOBAL MARKET ANALYSIS
3.1 Global Anticoagulants Market Analysis
3.1.1 Global Anticoagulants Market by Value
3.1.2 Global Anticoagulants Market Share by Treatment
3.1.3 Global Anticoagulants Market Share by Segment (Oral Anticoagulants and others)
3.1.4 Global Anticoagulants Market Share by Products (Lovenox, Arixtra, Xarelto, Eliquis, Pradaxa, and Savaysa)
4. GLOBAL ANTICOAGULANTS PRODUCT ANALYSIS
4.1 Injectable Anticoagulants Product Analysis
4.1.1 Global Lovenox Market by Value
4.1.2 Global Arixtra Market by Value
4.2 Oral Anticoagulants Product Analysis
4.2.1 Global Xarelto Market by Value
4.2.2 Global Eliquis Market by Value
4.2.3 Global Pradaxa Market by Value
4.2.4 Global Savaysa Market by Value
5. REGIONAL ANALYSIS
5.1 The US Anticoagulants Market Analysis
5.1.1 The US Anticoagulants Market by Value
5.1.2 The US Anticoagulants Market by Products (Xarelto, Eliquis, Pradaxa, and Savaysa)
5.1.3 The US Xarelto Market by Value
5.1.4 The US Eliquis Market by Value
5.1.5 The US Pradaxa Market by Value
5.1.6 The US Savaysa Market by Value
6. COMPETITIVE LANDSCAPE
6.1 Global Top Oral Anticoagulants by Sales
6.2 Global Anticoagulants Market Players by Product Comparison
7. COMPANY PROFILE
7.1 Bayer Group
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 BMS/Pfizer
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Boehringher Ingelheim
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Daiichi Sankyo
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
LIST OF FIGURES
Figure 1: Types of Anticoagulants
Figure 2: Global Anticoagulants Market by Value; 2013-2017 (US$ Billion)
Figure 3: Global Anticoagulants Market by Value; 2017-2022 (US$ Billion)
Figure 4: Global Anticoagulants Market Share by Treatment; 2015 (Percentage, %)
Figure 5: Global Anticoagulants Market Share by Segment; 2017 (Percentage, %)
Figure 6: Global Anticoagulants Market Share by Products; 2017 (Percentage, %)
Figure 7: Global Lovenox Market by Value; 2012-2017 (US$ Billion)
Figure 8: Global Arixtra Market by Value; 2015-2017 (US$ million)
Figure 9: Global Xarelto Market by Value; 2016-2022 (US$ Billion)
Figure 10: Global Eliquis Market by Value; 2016-2022 (US$ Billion)
Figure 11: Global Pradaxa Market by Value; 2016-2022(US$ Billion)
Figure 12: Global Savaysa Market by Value; 2016-2022 (US$ Million)
Figure 13: The US Anticoagulants Market by Value; 2016-2022(US$ Billion)
Figure 14: The US Anticoagulants Market by Products; 2017 (Percentage, %)
Figure 15: The US Xarelto Market by Value; 2016-2022(US$ Billion)
Figure 16: The US Eliquis Market by Value; 2016-2022(US$ Billion)
Figure 17: The US Pradaxa Market by Value; 2016-2022(US$ Million)
Figure 18: The US Savaysa Market by Value; 2016-2022(US$ Million)
Figure 19: Global Top Oral Anticoagulants by Sales; 2017 (US$ Billion)
Figure 20: Bayer Group Net Sales; 2012-2017 (US$ Billion)
Figure 21: Bayer Group Net Sales by Segment; 2017 (Percentage, %)
Figure 22: Bayer Group Net Sales by Geography; 2017 (Percentage, %)
Figure 23: BMS-Pfizer Alliance Revenue; 2014-2017 (US$ Billion)
Figure 24: BMS Revenue by Geography; 2017 (Percentage, %)
Figure 25: BMS Revenue by Product; 2017 (Percentage, %)
Figure 26: Boehringher Ingelheim Net Sales; 2012-2016 (US$ Billion)
Figure 27: Boehringher Ingelheim Net Sales by Geography; 2016 (Percentage, %)
Figure 28: Boehringher Ingelheim Net Sales by Business; 2016 (Percentage, %)
Figure 29: Daiichi Sankyo Revenue; 2012-2017 (US$ Billion)
Figure 30: Daiichi Sankyo Revenue by Geography; 2017 (Percentage, %)
Figure 1: Types of Anticoagulants
Figure 2: Global Anticoagulants Market by Value; 2013-2017 (US$ Billion)
Figure 3: Global Anticoagulants Market by Value; 2017-2022 (US$ Billion)
Figure 4: Global Anticoagulants Market Share by Treatment; 2015 (Percentage, %)
Figure 5: Global Anticoagulants Market Share by Segment; 2017 (Percentage, %)
Figure 6: Global Anticoagulants Market Share by Products; 2017 (Percentage, %)
Figure 7: Global Lovenox Market by Value; 2012-2017 (US$ Billion)
Figure 8: Global Arixtra Market by Value; 2015-2017 (US$ million)
Figure 9: Global Xarelto Market by Value; 2016-2022 (US$ Billion)
Figure 10: Global Eliquis Market by Value; 2016-2022 (US$ Billion)
Figure 11: Global Pradaxa Market by Value; 2016-2022(US$ Billion)
Figure 12: Global Savaysa Market by Value; 2016-2022 (US$ Million)
Figure 13: The US Anticoagulants Market by Value; 2016-2022(US$ Billion)
Figure 14: The US Anticoagulants Market by Products; 2017 (Percentage, %)
Figure 15: The US Xarelto Market by Value; 2016-2022(US$ Billion)
Figure 16: The US Eliquis Market by Value; 2016-2022(US$ Billion)
Figure 17: The US Pradaxa Market by Value; 2016-2022(US$ Million)
Figure 18: The US Savaysa Market by Value; 2016-2022(US$ Million)
Figure 19: Global Top Oral Anticoagulants by Sales; 2017 (US$ Billion)
Figure 20: Bayer Group Net Sales; 2012-2017 (US$ Billion)
Figure 21: Bayer Group Net Sales by Segment; 2017 (Percentage, %)
Figure 22: Bayer Group Net Sales by Geography; 2017 (Percentage, %)
Figure 23: BMS-Pfizer Alliance Revenue; 2014-2017 (US$ Billion)
Figure 24: BMS Revenue by Geography; 2017 (Percentage, %)
Figure 25: BMS Revenue by Product; 2017 (Percentage, %)
Figure 26: Boehringher Ingelheim Net Sales; 2012-2016 (US$ Billion)
Figure 27: Boehringher Ingelheim Net Sales by Geography; 2016 (Percentage, %)
Figure 28: Boehringher Ingelheim Net Sales by Business; 2016 (Percentage, %)
Figure 29: Daiichi Sankyo Revenue; 2012-2017 (US$ Billion)
Figure 30: Daiichi Sankyo Revenue by Geography; 2017 (Percentage, %)
LIST OF TABLES
Table 1: Unfractionated Heparin v/s Low Molecular Weight Heparin
Table 2: List of Intravenous/Subcutaneous Anticoagulants
Table 3: List of Oral Anticoagulants (NOCAs)
Table 4: Global Anticoagulants Market Players by Product Comparison
Table 5: Bayer Group Product and Activities of Pharmaceutical Segment
Table 6: Xarelto Research and Development Project (Phase III)
Table 7: Boehringher Ingelheim Product Review; 2016
Table 1: Unfractionated Heparin v/s Low Molecular Weight Heparin
Table 2: List of Intravenous/Subcutaneous Anticoagulants
Table 3: List of Oral Anticoagulants (NOCAs)
Table 4: Global Anticoagulants Market Players by Product Comparison
Table 5: Bayer Group Product and Activities of Pharmaceutical Segment
Table 6: Xarelto Research and Development Project (Phase III)
Table 7: Boehringher Ingelheim Product Review; 2016
